2021 UN Correspondents Association Awards for Best Journalistic Coverage of the United Nations and UN Agencies

WINNERS WILL BE HONORED BY THE UN SECRETARY-GENERAL H.E. ANTÓNIO GUTERRES DECEMBER 2021 (DATE TBD) IN NEW YORK

NEW YORK, June 24, 2021 /PRNewswire/ — The United Nations Correspondents Association (UNCA) invites media worldwide to submit entries for its 25th anniversary of the UNCA Awards for best print, broadcast (TV & Radio) and online, web-based media coverage of COVID-19, climate change and the United Nations, UN agencies and field operations.

United Nations Correspondents Association Logo

While the UNCA Awards 25th anniversary was put on hold in 2020 due to the coronavirus pandemic, this year the UN Correspondents Association will return to hosting the annual event in December, honoring excellence in journalism around the globe.

Deadline for submissions is September 15, 2021.

The awards are open to all journalists anywhere in the world.

The Awards are:

  1. The Elizabeth Neuffer Memorial Prize for coverage of the COVID-19 pandemic, sponsored by the Alexander Bodini Foundation. The prize is for print (including online media) and broadcast media (TV & Radio).
  2. The Prince Albert II of Monaco and UNCA Global Prize for Coverage of Climate Change. The prize is for print (including online media) and broadcast media (TV & Radio).
  3. The Ricardo Ortega Memorial Prize for coverage of the United Nations, UN agencies and field operations, sponsored by the United Nations Alliance of Civilizations. The prize is for print (including online media) and broadcast media (TV & Radio)

IMPORTANT INFORMATION FOR APPLICANTS:

Work in print, broadcast (TV & Radio) and online coverage must be published between September 2019 and August 2021.

The judges will look for entries with impact, insight, and originality, and will consider the courage and investigative and reporting skills of the journalists. Entries from the developing world media are particularly welcome.

Entries can be submitted in any of the official UN languages (English, French, Arabic, Chinese, Spanish, and Russian), however a written transcript in English or French is necessary to facilitate the judging process.

Each candidate can submit to no more than two (2) prize categories, with a maximum of two (2) stories in each. Joint entries are accepted.

Electronic files and web links uploaded to the online Entry Form are required.

HOW TO SUBMIT YOUR ENTRY:

Entries are submitted online by completing the UNCA Awards Entry Form.

On the first page, please complete your personal information and upload your photo.
The following page is where you will submit your work electronically by uploading web links and/or files directly to the Entry Form.

** Electronic entries are mandatory **

All entries must be received by September 15th, 2021

For Questions regarding UNCA Awards & entries please contact:
The UNCA Office, 1-212-963-7137.
Or send an email to [email protected]

CLICK ON THE ENTRY FORM BELOW TO GET STARTED:
ENTRY FORM
http://unca.com/unca-awards-call-for-submissions-form/

UNCA Awards Committee: Valeria Robecco (UNCA President), Giampaolo Pioli (Awards Chairman), Tuyet Nguyen (Awards Selections Coordinator), Sherwin Bryce-Pease (UNCA Executive Member), Edith Lederer (UNCA Executive Member), Linda Fasulo (UNCA Executive Member)

Logo – https://mma.prnewswire.com/media/1550296/United_Nations_Correspondents_Association_Logo.jpg

Graduate Management Admission Council Welcomes New Members to the Board

New additions reflect the diverse, global perspective of the business school community

RESTON, Va., June 23, 2021 (GLOBE NEWSWIRE) — The Graduate Management Admission Council™ (GMAC™), a global association of leading graduate business schools, today announced the addition of four new members to its board of directors. Katy Montgomery, Associate Dean, Degree Programmes, INSEAD; François Ortalo-Magné, Dean, London Business School; and Giuseppe Soda, Dean, SDA Bocconi School of Management, Bocconi University, will begin their terms on July 1. In addition, Yuan Ding, Vice President and Dean of China Europe International Business School (CEIBS), was appointed as a board director in January this year to fill the seat vacated by Enase Okonedo of the Pan-Atlantic University.

“GMAC’s new board of directors represent leading business schools with campuses located in 10 countries across Europe, Asia, North America, Africa, and the Middle East,” said Sangeet Chowfla, president and CEO of GMAC. “As student mobility returns and regains in the post-pandemic world, I look forward to working alongside this diverse group of leaders ― and the rest of the GMAC board ― to continue to advance GMAC’s vision to ensure that all talented individuals can benefit from the best business education for them.”

New GMAC Board Members

Yuan Ding, Vice President and Dean, Cathay Capital Chair in Accounting, CEIBS

Yuan Ding is Vice President and Dean and the Cathay Capital Chair Professor in Accounting at CEIBS, where he has been honored three times with the CEIBS Teaching Excellence Award. Prior to joining CEIBS, he was a tenured faculty member of the HEC School of Management, Paris, France. He is a member of the European Accounting Association, French Accounting Association and American Accounting Association. He holds a PhD in Accounting from the Institute of Enterprises Administration at the University Montesquieu Bordeaux IV, France, as well as a Master’s in Enterprises Administration from the University of Poitiers, France. Ding is the author of multiple books on financial reporting and his research appears in leading academic journals.

Katy Montgomery, Associate Dean, Degree Programmes, INSEAD

As the INSEAD Associate Dean of Degree Programmes, Montgomery is responsible for the commercial leadership of the INSEAD Degree Programme portfolio across four campuses: Fontainebleau, Singapore, Abu Dhabi, and San Francisco. Her functional responsibilities include strategy, marketing, sales, admissions, financial aid and scholarships, programme operations, student life, psychological services, and career services. Prior to joining INSEAD, she served as Associate Dean of Student Development at Johns Hopkins Carey Business School. Montgomery holds a degree in Political Science from Loyola University New Orleans and a Juris Doctor degree from Georgetown University Law Center.

François Ortalo-Magné, Dean, London Business School

François Ortalo-Magné is the ninth Dean of London Business School (LBS), a position he has held since August 2017. He is leading a strategy focused on (1) academic research and its impact, (2) learning innovations and alumni engagement and (3) inclusion, striving for gender parity and greater socio-economic and ethnic diversity. Since taking up the role, Ortalo-Magné has led the relaunch of the LBS brand, the growth of degree programmes and a significant increase in philanthropic support for scholarships. His research on the economics of land and housing markets has been published in leading academic journals. He has built on his research and leadership experiences to advise a broad range of private, governmental and multi-lateral organisations and share his insights in leading media outlets and at conferences around the world. Prior to his appointment, Ortalo-Magné was the Albert O. Nicholas Dean and Robert E. Wangard Professor of Real Estate at the Wisconsin School of Business. His first academic appointment was at the London School of Economics.

Giuseppe Soda, Dean, SDA Bocconi School of Management, Bocconi University

Giuseppe “Beppe” Soda is the Dean of SDA Bocconi School of Management and Full Professor of Organization Theory and Network Analysis at Bocconi University. Before becoming Dean in 2016, his roles have included serving as the Associate Dean for Research (2007-2013), Director of the Department of Management and Technology (2013-2016) and Head of Organization and HRM Department (2001-2006). He is also serving EFMD as member of the EQUIS Accreditation Board. Soda’s research investigates the performance consequences of the interplay between organizational architectures and organizational networks and his work has been published in top academic management journals.

Besides the aforementioned newly elected board members, Martin Boehm, Professor of Marketing and former Dean of IE Business School and soon the new Rector of EBS Universität für Wirtschaft und Recht, and Themin Suwardy, Dean of Postgraduate Professional Programmes, Singapore Management University, were re-elected for a second term.

GMAC also recognizes its outgoing board members, Leila Guerra, Vice Dean (Education) of Imperial College Business School, and Peter Tufano, Peter Moores Dean and Professor of Finance of Saïd Business School, University of Oxford. GMAC thanks them for their service in the past nearly four years to our organization and contributions to the graduate management education community.

About GMAC

The Graduate Management Admission Council™ (GMAC™) is a mission-driven association of leading graduate business schools worldwide. Founded in 1953, GMAC creates solutions and experiences that enable business schools and candidates to better discover, evaluate, and connect with each other.

GMAC provides world-class research, industry conferences, recruiting tools, and assessments for the graduate management education industry, as well as tools, resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test™ (GMAT™) exam is the most widely used graduate business school assessment.

GMAC also owns and administers the NMAT by GMAC™ (NMAT™) exam and the Executive Assessment (EA). More than 7 million candidates on their business master’s or MBA journey visited GMAC’s mba.com last year to explore business school options, prepare and register for exams, and get advice on the admissions process. BusinessBecause and The MBA Tour are subsidiaries of GMAC, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit www.gmac.com.

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
202-390-4180 (mobile)
[email protected]

Conformis, Inc. Announces Exclusive Distribution Agreement in China

New Agreement expands Conformis’ global reach and brings patient-specific knee replacement systems to the largest market in the Asia-Pacific region

BILLERICA, Mass., June 23, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) today announced the execution of an agreement to enter the Asia-Pacific market through an exclusive distribution relationship with XR Medical Group (Hong Kong) Limited (XR Medical).

Under the distribution agreement, XR Medical will have exclusive rights for the sale, marketing, and distribution of Conformis’ patient-specific iTotal® CR & PS total knee replacement systems, iTotal® CR & PS patella devices, and iUni® and iDuo® partial knee replacement systems. Other products, such as Conformis’ recently approved Identity Imprint™ knee system and its hip portfolio of products, may be added in the future.

XR Medical’s sales team will provide sales and support exclusively to top-tier facilities in Hainan’s Boao Lecheng International Medical Tourism Pilot Zone (Pilot Zone) on behalf of Conformis. The region is a major center of medical tourism for dozens of countries.

“This distribution agreement is another example of progress as we execute our overall growth strategy. We are confident that our unique product portfolio will serve to accelerate Conformis’ international growth. And we are pleased to partner with XR Medical, which has an impressive track record of success in China,” said Mark Augusti, President and CEO of Conformis. “What is particularly attractive about XR Medical is its strong performance in the Pilot Zone. With access to patients visiting the region for treatment, this creates an opportunity to introduce a broad audience to the clinical benefits of Conformis technology. We believe that starting in the Pilot Zone positions us well and we anticipate that this relationship will serve as a model for future expansion opportunities in mainland China.”

The Pilot Zone is located on Hainan, a large island off China’s southern coast. It was established in 2019 to attract affluent Chinese citizens who might otherwise go abroad for their medical care. This region of China has developed top-level medical treatment facilities in a popular destination. Currently, medical tourists from dozens of countries, including those in Southeast Asia, are permitted to visit Hainan for a 30-day stay without visas.

The global market for knee joint reconstruction is projected at more than $9 billion. Of this total, the knee joint reconstruction market in the Asia-Pacific region is currently estimated to exceed $1.7 billion. Fortune Business Insights predicts a high growth rate for knee replacements in the region due to the combination of the increased prevalence of knee disorders, booming medical tourism, increased disposable incomes, and improved healthcare infrastructure.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and standard implants, along with single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal® CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. You should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Source: Conformis, Inc.

Media Contact:
Investor Relations
[email protected]
(781) 374-5598

Liquid Instruments Introduces Moku:Pro – A High Performance, Software-Defined Instrumentation Platform for Engineers and Scientists

New architecture delivers nine instruments with real-time measurement capabilities to the research lab

Moku:Pro In Lab Setting

Moku:Pro brings test and measurement into the modern age, allowing engineers and researchers to dynamically switch between instruments rather than needing multiple stand-alone devices.

CANBERRA, Australia and SAN DIEGO, June 23, 2021 (GLOBE NEWSWIRE) — Liquid Instruments, an innovator in precision software-defined instrumentation, today announced Moku:Pro, a high-performance platform for engineering and research labs.

Moku:Pro accelerates the transition from traditional fixed-function test and measurement hardware to a flexible field-programmable gate array (FPGA)-based approach by making high-quality instruments accessible in an integrated, software-upgradeable platform.

“Researchers in engineering and physics face constantly evolving requirements – with changes occurring on timescales much shorter than the lifespan of test equipment,” said Daniel Shaddock, CEO of Liquid Instruments. “Moku:Pro’s software-enabled-hardware architecture allows it to evolve as your applications evolve, something that is simply not possible with conventional test equipment.”

Moku:Pro hosts nine powerful instruments, including an oscilloscope, lock-in amplifier, PID controller, phasemeter, arbitrary waveform generator, data logger, spectrum analyzer, frequency response analyzer, and waveform generator to ensure researchers have the instrumentation they need to quickly characterize their set up and scale their experiments. The platform was designed to meet the needs of researchers in a variety of fields, from aerospace to semiconductor. Moku:Pro’s instrument suite is particularly suited to photonics applications, including spectroscopy, microscopy, metrology, gravitational wave detection, active laser stabilization, and quantum computing.

Moku:Pro

Moku:Pro accelerates the transition from traditional fixed-function test and measurement hardware to a flexible field-programmable gate array (FPGA)-based approach by making high-quality instruments accessible in an integrated, software-upgradeable platform.

“Quantum computing pushes the performance limits of electronics, optics, and flexible real-time signal processing. We see software-defined instrumentation as the future of test and measurement systems for quantum computing,” said Andrew Horsley, CEO and Co-founder of Quantum Brilliance, a full-stack quantum computing company working on room temperature diamond technology.  “Moku:Pro is a workhorse of the lab and one of the most versatile photonics tools we’ve seen.”

Bringing Instrumentation Into the Modern Era
Moku:Pro brings test and measurement into the modern age, allowing engineers and researchers to dynamically switch between instruments rather than needing multiple stand-alone devices.  Advanced ADC blending technology ensures that each instrument can function with optimal sensitivity from RF to acoustic frequencies without compromising performance for flexibility. Full connectivity via Wi-Fi, Ethernet, and USB-C ensures industry-standard, hassle-free configuration.

A key benefit of software-defined instrumentation is that it gets better over time. Moku:Pro can receive over-the-air updates to deliver improved specifications, new instruments, or entirely new capabilities. Users can expect to see these benefits as soon as September when Liquid Instruments plans to release a feature that will give Moku:Pro the ability to run multiple instruments in conjunction with one another and hot-swap instruments in and out. In this multi-instrument mode, instruments can be combined and connected to form sophisticated signal-processing pipelines. Also slated for September release is a new cloud-based tool that will allow users to directly program Moku:Pro’s FPGA. With this capability, users can implement unique signal processing algorithms and create their own custom instruments, which will further widen the gap with conventional hardware.

Moku:Pro Specifications

  • 4 analog inputs and outputs
  • Blended ADC input (10-bit+18-bit) for low noise, high bandwidth applications
  • Sampling rate of 5 GSa/s (1 channel), 1.25 GSa/s (4 channels)
  • 9 integrated instruments, including a DC-600 MHz lock-in amplifier
  • 120 GB SSD for high-speed onboard storage
  • API support for Python and MATLAB
  • Starting at $12,000 for the base configuration, ranging up to $20,000 for the full suite.

A History of Success 
The Liquid Instruments technical leadership team brings deep expertise in complex measurements with experience from Australian National University, Max Planck Institute, Lockheed Martin, Caltech, and NASA’s Jet Propulsion Laboratory.  Moku:Pro expands the line of software-defined solutions from Moku:Lab, a twelve-instrument platform for research, and, more recently, Moku:Go, a complete and portable lab solution for undergraduate education.

For more information on Moku:Pro, visit: liquidinstruments.com

About Liquid Instruments
Liquid Instruments is a leader in precision software-defined instrumentation and is revolutionizing the way that students, engineers, and scientists learn, work, and discover. Their product line of hardware and software solutions leverages the computational power of modern FPGAs to create highly customizable instrumentation for controlling experiments and acquiring and analyzing data. The team’s IP in software-defined hardware enables Moku products to be dynamically reconfigurable in the field, serving a wide range of ever-changing experimental and process control situations. For more information, visit https://liquidinstruments.com.

The Project received funding from The Australian Government. Liquid Instruments gratefully acknowledges funding and support of the Australian Commonwealth Government through the CRC-P program administered by the Department of Industry Innovation and Science.

Media Contact
Codeword for Liquid Instruments
liquidinstruments@codewordagency.com
801-703-4092

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/37cb06a3-2242-4fe9-b6d2-0243a826051f

https://www.globenewswire.com/NewsRoom/AttachmentNg/8e84cd5f-7bf1-4276-9950-f57a12cfac19

New architecture delivers nine instruments with real-time measurement capabilities to the research lab

Moku:Pro In Lab Setting

Moku:Pro brings test and measurement into the modern age, allowing engineers and researchers to dynamically switch between instruments rather than needing multiple stand-alone devices.

CANBERRA, Australia and SAN DIEGO, June 23, 2021 (GLOBE NEWSWIRE) — Liquid Instruments, an innovator in precision software-defined instrumentation, today announced Moku:Pro, a high-performance platform for engineering and research labs.

Moku:Pro accelerates the transition from traditional fixed-function test and measurement hardware to a flexible field-programmable gate array (FPGA)-based approach by making high-quality instruments accessible in an integrated, software-upgradeable platform.

“Researchers in engineering and physics face constantly evolving requirements – with changes occurring on timescales much shorter than the lifespan of test equipment,” said Daniel Shaddock, CEO of Liquid Instruments. “Moku:Pro’s software-enabled-hardware architecture allows it to evolve as your applications evolve, something that is simply not possible with conventional test equipment.”

Moku:Pro hosts nine powerful instruments, including an oscilloscope, lock-in amplifier, PID controller, phasemeter, arbitrary waveform generator, data logger, spectrum analyzer, frequency response analyzer, and waveform generator to ensure researchers have the instrumentation they need to quickly characterize their set up and scale their experiments. The platform was designed to meet the needs of researchers in a variety of fields, from aerospace to semiconductor. Moku:Pro’s instrument suite is particularly suited to photonics applications, including spectroscopy, microscopy, metrology, gravitational wave detection, active laser stabilization, and quantum computing.

Moku:Pro

Moku:Pro accelerates the transition from traditional fixed-function test and measurement hardware to a flexible field-programmable gate array (FPGA)-based approach by making high-quality instruments accessible in an integrated, software-upgradeable platform.

“Quantum computing pushes the performance limits of electronics, optics, and flexible real-time signal processing. We see software-defined instrumentation as the future of test and measurement systems for quantum computing,” said Andrew Horsley, CEO and Co-founder of Quantum Brilliance, a full-stack quantum computing company working on room temperature diamond technology.  “Moku:Pro is a workhorse of the lab and one of the most versatile photonics tools we’ve seen.”

Bringing Instrumentation Into the Modern Era
Moku:Pro brings test and measurement into the modern age, allowing engineers and researchers to dynamically switch between instruments rather than needing multiple stand-alone devices.  Advanced ADC blending technology ensures that each instrument can function with optimal sensitivity from RF to acoustic frequencies without compromising performance for flexibility. Full connectivity via Wi-Fi, Ethernet, and USB-C ensures industry-standard, hassle-free configuration.

A key benefit of software-defined instrumentation is that it gets better over time. Moku:Pro can receive over-the-air updates to deliver improved specifications, new instruments, or entirely new capabilities. Users can expect to see these benefits as soon as September when Liquid Instruments plans to release a feature that will give Moku:Pro the ability to run multiple instruments in conjunction with one another and hot-swap instruments in and out. In this multi-instrument mode, instruments can be combined and connected to form sophisticated signal-processing pipelines. Also slated for September release is a new cloud-based tool that will allow users to directly program Moku:Pro’s FPGA. With this capability, users can implement unique signal processing algorithms and create their own custom instruments, which will further widen the gap with conventional hardware.

Moku:Pro Specifications

  • 4 analog inputs and outputs
  • Blended ADC input (10-bit+18-bit) for low noise, high bandwidth applications
  • Sampling rate of 5 GSa/s (1 channel), 1.25 GSa/s (4 channels)
  • 9 integrated instruments, including a DC-600 MHz lock-in amplifier
  • 120 GB SSD for high-speed onboard storage
  • API support for Python and MATLAB
  • Starting at $12,000 for the base configuration, ranging up to $20,000 for the full suite.

A History of Success 
The Liquid Instruments technical leadership team brings deep expertise in complex measurements with experience from Australian National University, Max Planck Institute, Lockheed Martin, Caltech, and NASA’s Jet Propulsion Laboratory.  Moku:Pro expands the line of software-defined solutions from Moku:Lab, a twelve-instrument platform for research, and, more recently, Moku:Go, a complete and portable lab solution for undergraduate education.

For more information on Moku:Pro, visit: liquidinstruments.com

About Liquid Instruments
Liquid Instruments is a leader in precision software-defined instrumentation and is revolutionizing the way that students, engineers, and scientists learn, work, and discover. Their product line of hardware and software solutions leverages the computational power of modern FPGAs to create highly customizable instrumentation for controlling experiments and acquiring and analyzing data. The team’s IP in software-defined hardware enables Moku products to be dynamically reconfigurable in the field, serving a wide range of ever-changing experimental and process control situations. For more information, visit https://liquidinstruments.com.

The Project received funding from The Australian Government. Liquid Instruments gratefully acknowledges funding and support of the Australian Commonwealth Government through the CRC-P program administered by the Department of Industry Innovation and Science.

Media Contact
Codeword for Liquid Instruments
liquidinstruments@codewordagency.com
801-703-4092

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/37cb06a3-2242-4fe9-b6d2-0243a826051f

https://www.globenewswire.com/NewsRoom/AttachmentNg/8e84cd5f-7bf1-4276-9950-f57a12cfac19

Centrient Pharmaceuticals boosting statins API manufacturing capacity

Rotterdam, The Netherlands, June 21, 2021 (GLOBE NEWSWIRE) —

Summary:

  • Centrient Pharmaceuticals has started production at its newly built statins API manufacturing unit in Toansa, India.
  • With this expansion the company is doubling its production capacity of Atorvastatin and Rosuvastatin, meeting the increased demand for its high-quality uniquely produced statins.
  • Centrient Pharmaceuticals’ statins are one of the most sustainably produced in the industry by eliminating harmful solvents, generating less waste, and a reduced carbon footprint of 32% as compared to traditional manufacturers.
  • Using backward integrated manufacturing methods, and dedicated production facilities, Centrient Pharmaceuticals is able to offer its customers security of supply.

Centrient Pharmaceuticals (“Centrient”), the global leader in sustainable antibiotics, next-generation statins and anti-fungals, announced today to have started production at its new statins manufacturing unit. With the building of its second dedicated unit on the Toansa site in India now completed, the company will double its statins production capacity. This will enable Centrient to meet growing demand for its sustainably manufactured Atorvastatin and Rosuvastatin Active Pharmaceutical Ingredients (APIs).

Statins are currently the most prescribed drug class globally for the treatment of high cholesterol and cardiovascular diseases and are among the top-selling drugs worldwide. The markets for Atorvastatin and Rosuvastatin in particular, has shown steady growth in the past years, as a result of the continued global prevalence of high cholesterol issues, replacement of older generation statins, and genericization of the market.

Starting almost a decade ago, Centrient has grown today into one of the leading statin API suppliers worldwide, servicing large pharma companies around the globe.

Next to high-quality features like long shelf life and large batch sizes, the company offers security of supply to customers through its dedicated statins production facility and backward integration. Being backward integrated, Centrient is independent from external imports of starting materials. Its enzymatic route of synthesis and patented technology minimise the use of harmful solvents, generate less waste, and reduce the company’s carbon footprint by 32% as compared to traditional manufacturers.

The news of the facility expansion follows major milestones on statins that the company reached in the past years. In 2012, under the name of DSM Sinochem Pharmaceuticals, it was the first pharmaceutical manufacturer worldwide to offer generic Atorvastatin APIs under a Certificate of Suitability to the Monograph of the European Pharmacopoeia (CEP). Since 2014, it has produced the unique Atorvastatin APIs in its state-of-the-art facility in Toansa, India for third-party customers.

In addition, the company was one of the first three companies worldwide that started to offer generic Rosuvastatin APIs under CEP in 2016. Two years later, the first generic Rosuvastatin and Atorvastatin finished dosage forms were launched in Western Europe.

“With the doubling of our production capacity, we demonstrate our commitment to maintain our leadership position in line with our strategy and to continue supporting our customers’ business growth. Guided by our brand promise of Quality, Reliability, and Sustainability, Centrient’s Rosuvastatin and Atorvastatin offer superior performance in all three areas to the benefit of our customers and the environment.”, says Frans Vlaar, Chief Commercial Officer at Centrient.

Ground breaking of the new manufacturing unit started at the end of 2019 and commercial supplies from the new unit will start in mid-2021With the new manufacturing line being operational and doubling the production capacity, Centrient will be even better positioned to secure supply, meeting the growing demand from customers and helping to improve the lives of patients who are in need of these medicine.

“We are extremely proud that we have been able to complete this project in a timely way given the challenges of executing such a complex project in the midst of the COVID pandemic,” says Jim McPherson, Chief Quality & Technical Operations Officer. “It reinforces our absolute commitment to meet the expectations of our customers as a partner of choice – delivering reliable and secure supply using leading sustainable technologies. The facility incorporates design features that allow further improvements in GMP and energy utilization, and enable greater automation for improved process control.”

———————————————————————————————————————————–


About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and antifungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms.

We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2200 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.

Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.

For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E-Mail: alice.beijersbergen@centrient.com.

Forward-looking statements
This press release may contain forward-looking statements with respect to Centrient Pharmaceuticals’ future financial performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.

Alice Beijersbergen
Centrient Pharmaceuticals
alice.beijersbergen@centrient.com